Business Context and Reporting Period
This Form 8-K Current Report was filed by Bone Biologics Corporation on July 31, 2017. The registrant is an emerging growth company incorporated in Delaware. The report primarily addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report does not contain financial statements or operational metrics.
Material Changes
The material change reported is the appointment of Bret Conrad Hankey to the Company's Board of Directors, effective July 31, 2017. Mr. Hankey, age 40, brings experience from the Hankey Group and Westlake Financial Services, specializing in automotive, finance, technology, real estate, and insurance sectors.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The only event noted is the issuance of a press release on August 3, 2017, regarding the board appointment.
Investor Verification Checklist
- Verify the qualifications and potential conflicts of interest of the newly appointed director, Bret Conrad Hankey.
- Confirm the date of the press release (August 3, 2017) referenced in Exhibit 99.1.
- Note that this filing does not update financial status; refer to the most recent 10-K or 10-Q for financial data.